Historical Valuation
Belite Bio Inc (BLTE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -35.75. The fair price of Belite Bio Inc (BLTE) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：162.31
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Belite Bio Inc (BLTE) has a current Price-to-Book (P/B) ratio of 20.28. Compared to its 3-year average P/B ratio of 15.26 , the current P/B ratio is approximately 32.90% higher. Relative to its 5-year average P/B ratio of 13.07, the current P/B ratio is about 55.18% higher. Belite Bio Inc (BLTE) has a Forward Free Cash Flow (FCF) yield of approximately -0.52%. Compared to its 3-year average FCF yield of -0.42%, the current FCF yield is approximately 23.35% lower. Relative to its 5-year average FCF yield of -0.35% , the current FCF yield is about 48.80% lower.
P/B
Median3y
15.26
Median5y
13.07
FCF Yield
Median3y
-0.42
Median5y
-0.35
Competitors Valuation Multiple
AI Analysis for BLTE
The average P/S ratio for BLTE competitors is 7.30, providing a benchmark for relative valuation. Belite Bio Inc Corp (BLTE.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BLTE
1Y
3Y
5Y
Market capitalization of BLTE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BLTE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BLTE currently overvalued or undervalued?
Belite Bio Inc (BLTE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -35.75. The fair price of Belite Bio Inc (BLTE) is between to according to relative valuation methord.
What is Belite Bio Inc (BLTE) fair value?
BLTE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Belite Bio Inc (BLTE) is between to according to relative valuation methord.
How does BLTE's valuation metrics compare to the industry average?
The average P/S ratio for BLTE's competitors is 7.30, providing a benchmark for relative valuation. Belite Bio Inc Corp (BLTE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Belite Bio Inc (BLTE) as of Jan 09 2026?
As of Jan 09 2026, Belite Bio Inc (BLTE) has a P/B ratio of 20.28. This indicates that the market values BLTE at 20.28 times its book value.
What is the current FCF Yield for Belite Bio Inc (BLTE) as of Jan 09 2026?
As of Jan 09 2026, Belite Bio Inc (BLTE) has a FCF Yield of -0.52%. This means that for every dollar of Belite Bio Inc’s market capitalization, the company generates -0.52 cents in free cash flow.
What is the current Forward P/E ratio for Belite Bio Inc (BLTE) as of Jan 09 2026?
As of Jan 09 2026, Belite Bio Inc (BLTE) has a Forward P/E ratio of -69.35. This means the market is willing to pay $-69.35 for every dollar of Belite Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Belite Bio Inc (BLTE) as of Jan 09 2026?
As of Jan 09 2026, Belite Bio Inc (BLTE) has a Forward P/S ratio of 0.00. This means the market is valuing BLTE at $0.00 for every dollar of expected revenue over the next 12 months.